Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Benitez Hidalgo, Olga; Bescós Cabestre, Agustí; Juarez Giménez, Juan Carlos; Gironella Mesa, Mercedes; Bosch, Francesc; Martinez Garcia, Maria Fernanda

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Benitez Hidalgo, Olga
dc.contributor.author	Bescós Cabestre, Agustí
dc.contributor.author	Juarez Giménez, Juan Carlos
dc.contributor.author	Gironella Mesa, Mercedes
dc.contributor.author	Bosch, Francesc
dc.contributor.author	Martinez Garcia, Maria Fernanda
dc.date.accessioned	2022-09-07T12:11:18Z
dc.date.available	2022-09-07T12:11:18Z
dc.date.issued	2022-05
dc.identifier.citation	Benitez Hidalgo O, Martinez Garcia MF, Bescos Cabestre A, Juarez Gimenez JC, Gironella Mesa M, Bosch Albareda F. Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management. Clin Case Reports. 2022 May;10(5):e05848.
dc.identifier.issn	2050-0904
dc.identifier.uri	https://hdl.handle.net/11351/8056
dc.description	Anesthesia; Haemophilia B; Neurosurgery
dc.description.abstract	Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.
dc.language.iso	eng
dc.publisher	Wiley
dc.relation.ispartofseries	Clinical Case Reports;10(5)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Sistema nerviós - Cirurgia
dc.subject	Hemofília - Tractament
dc.subject	Proteïnes recombinants - Ús terapèutic
dc.subject.mesh	Hemophilia B
dc.subject.mesh	/drug therapy
dc.subject.mesh	Neurosurgery
dc.subject.mesh	Recombinant Fusion Proteins
dc.title	Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1002/ccr3.5848
dc.subject.decs	hemofilia B
dc.subject.decs	/farmacoterapia
dc.subject.decs	neurocirugía
dc.subject.decs	proteínas de fusión recombinantes
dc.relation.publishversion	https://doi.org/10.1002/ccr3.5848
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Benitez Hidalgo O, Martinez Garcia MF, Gironella Mesa M, Bosch Albareda F] Experimental Hematology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bescos Cabestre A] Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Juarez Gimenez JC] Servei de Farmàcia Hospitalària, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	35620255
dc.identifier.wos	000798984900001
dc.rights.accessrights	info:eu-repo/semantics/openAccess